| 224 The MHC-II Transactivator, CIITA, Inhibits Tat-Mediated HIV-1 LTR Transactivation and Virus Replication in Human U937 Monocytic Cells G Forlani, A Kajaste-Rudnitski, E Vicenzi, G Poli, R Accolla, G Tosi JAIDS Journal of Acquired Immune Deficiency Syndromes 56, 97, 2011 | | 2011 |
| 231 The MHC Class II Transactivator, CIITA, is a Viral Restriction Factor for Human Oncogenic Retroviruses G Tosi, G Forlani, V Andresen, M Turci, U Bertazzoni, G Franchini, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 56, 100, 2011 | | 2011 |
| A Panel of Eight miRNAs Is Deregulated in HTLV-2 Infected PBMCs and BJABGu Cell Line E Pilotti, A Cannata, G Magnani, F Bignami, A Corsi, MT Valenti, ... International Journal of Molecular Sciences 23 (14), 7583, 2022 | | 2022 |
| A-104 Tracing the intracellular journey of HTLV-1 HBZ during infection: From asymptomatic carriers to HAM/TSP ending to ATL: A one-way ticket? M Baratella, G Forlani, A Gessain, S Jacobson, R Accolla JAIDS Journal of Acquired Immune Deficiency Syndromes 81, 32, 2019 | | 2019 |
| Abstract A014: CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity FBN Eddine, G Forlani, G Tosi, RS Accolla Cancer Immunology Research 4 (11_Supplement), A014-A014, 2016 | | 2016 |
| Abstract B047: Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment RS Accolla, G Forlani, G Tosi Cancer Immunology Research 4 (1_Supplement), B047-B047, 2016 | | 2016 |
| Abstract B048: The MHC class II transactivator CIITA inhibits the persistent activation of NF-kB by Human T cell Lymphotropic Virus type-1 Tax-1 oncoprotein G Forlani, R Abdallah, RS Accolla, G Tosi Cancer Immunology Research 4 (1_Supplement), B048-B048, 2016 | | 2016 |
| Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma L Buonaguro, A Mayer, M Loeffler, S Missel, R Accolla, YT Ma, ... Cancer Research 80 (16_Supplement), LB-094-LB-094, 2020 | 5 | 2020 |
| Altered sodium binding induced by K448E mutation in the extracellular loop 5 of GAT1 GABA transporter G Forlani, E Bossi, S Giovannardi, A Peres | | 2000 |
| An episode of oral mucositis after the first administration of the ChAdOx1 COVID‐19 vaccine L Azzi, M Toia, N Stevanello, F Maggi, G Forlani Oral diseases, 2021 | 19 | 2021 |
| Association of the neuron specific Ras-exchange factor Ras-GRF1 with the microtubules cytoskeleton G Forlani, P Lavagni, M Gugiatti, E Ragni, L Popolo, E Sturani, R Zippel 5th Convegno della Federazione Italiana Scienze della Vita, Atti, 332-332, 2003 | | 2003 |
| Autoimmunità e Malattie Autoimmuni R Accolla, G Forlani, G Tosi Le Malattie Autoimmuni 1, 3-10, 2017 | | 2017 |
| Biophysics and molecular physiology of membrane transport systems S Giovannardi, E Bossi, G Forlani, F Binda, A Peres | | 2001 |
| Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: a critical issue for triggering protective immunity and re-orienting the tumor … RS Accolla, L Lombardo, R Abdallah, G Raval, G Forlani, G Tosi Frontiers in oncology 4, 32, 2014 | 60 | 2014 |
| CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity F BOU NASSER EDDINE, G Forlani, G Tosi, R Accolla CANCER IMMUNOLOGY RESEARCH 4, 14-14, 2016 | | 2016 |
| CIITA-driven MHC class II expressing tumor cells as antigen presenting cell performers: toward the construction of an optimal anti-tumor vaccine RS Accolla, E Ramia, A Tedeschi, G Forlani Frontiers in immunology 10, 1806, 2019 | 82 | 2019 |
| CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor … F Bou Nasser Eddine, G Forlani, L Lombardo, A Tedeschi, G Tosi, ... Oncoimmunology 6 (1), e1261777, 2017 | 34 | 2017 |
| CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new … E Ramia, AM Chiaravalli, F Bou Nasser Eddine, A Tedeschi, F Sessa, ... Oncoimmunology 8 (3), 1548243, 2019 | 28 | 2019 |
| CIITA-transduced glioblastoma cells uncover a rich repertoire of clinically relevant tumor-associated HLA-II antigens G Forlani, J Michaux, HS Pak, F Huber, ELM Joseph, E Ramia, ... Molecular & Cellular Proteomics 20, 2021 | 25 | 2021 |
| CIITA-transfected tumor cells as potent, widely applicable anti-tumor vaccine due to their optimal triggering of long-lasting tumor-specific CD4+ T helper cells G Capone, L Lombardo, PL Lollini, R Accolla, G Forlani MINERVA MEDICA 102, 172-172, 2011 | | 2011 |
